Source comparison
Thymosin Alpha-1 Studied Alopecia Areata: Treatment vs Research Protocols
Dosing 1.6mg subcutaneous, twice weekly for 12–24 weeks Same dosing, extended to 24–36 weeks in non-responders 1.6mg twice weekly + tofacitinib 5mg daily Research protocols use fixed duration; clinical use often extends based on response. Combination with JAK
This comparison does not assign a generated winner or score.
- Dosing
- 1.6mg subcutaneous, twice weekly for 12–24 weeks
- Same dosing, extended to 24–36 weeks in non-responders
- 1.6mg twice weekly + tofacitinib 5mg daily
- Research protocols use fixed duration; clinical use often extends based on response. Combination with JAK inhibitors is unstudied but mechanistically rational.
- Expected Outcome
- 17–39% complete regrowth in patchy AA (disease <18 months)
- 30–50% partial regrowth; higher relapse post-treatment
- Potentially additive. JAK blocks cytokine signaling, thymosin modulates T-cell populations
- Thymosin alpha-1 alone rarely achieves complete regrowth in severe cases. Response strongly predicted by disease duration and pattern.
- Administration
- Subcutaneous injection, sterile reconstitution required
- Same. Oral or topical forms have no documented efficacy
- Sequential or concurrent injection timing varies by protocol
- Peptide must be refrigerated post-reconstitution (2–8°C) and used within 28 days to maintain stability.
- Cost Range
- $400–800 per 12-week course (research-grade peptide)
- $600–1200 per 12-week course (compounded or clinical-grade)
- $1400–2000/month (thymosin + generic tofacitinib)
- Cost-effectiveness depends entirely on response. Non-responders (55–70% of patients) gain zero benefit.
- Safety Profile
- Minimal adverse events; injection site reactions in 15–20%
- Same. No systemic immunosuppression documented
- JAK inhibitors carry infection risk; thymosin doesn't add additional immunosuppression
- Thymosin alpha-1 is safer than corticosteroids or JAK inhibitors but also less consistently effective.
- Bottom Line
- Thymosin alpha-1 works through immune modulation, not follicular growth factors. Response is all-or-nothing by week 12, and relapse rates are high. It's worth trying in early-stage patchy disease (<18 months, <50% scalp involvement) but unlikely to benefit severe, long-standing, or ophiasis-pattern cases.
- Combination protocols with JAK inhibitors make mechanistic sense but lack clinical trial validation. The peptide's immune effects complement rather than overlap with JAK inhibition, potentially reducing relapse when both are used sequentially or concurrently.